Olaparib + Abiraterone Gets Priority Review for Castration-Resistant Prostate Cancer
The sNDA is supported by data from the phase 3 PROpel trial which included adults with mCRPC in the first-line setting.
Diagnosis & Disease Information
New Indication for Nubeqa: Metastatic Hormone-Sensitive Prostate Cancer
The approval was based on data from the phase 3 ARASENS trial.
Talabostat Plus Pembrolizumab Promising for mCRPC With Adenocarcinoma Phenotype
At a median follow-up of 12 weeks, results showed that the composite response rate was 23%.
Continued Enzalutamide Tx Beneficial in mCRPC Patients With Progressive Disease
The PRESIDE trial included 687 chemotherapy-naïve patients with mCRPC who had progressive disease while on androgen deprivation therapy or following bilateral orchiectomy.
Statin Use Not Associated With Survival Benefits in mCRPC Patients
The analysis included 4919 patients, of which 19.7% (n=969) had received a lipophilic statin and 9.2% (n=452) had received a hydrophilic statin.
Merck Halts Trial Evaluating Combo Therapy for Metastatic Castration-Resistant Prostate Cancer
Following a planned interim analysis, the decision to halt the trial was made after a review of data by an independent Data Monitoring Committee.
Relugolix Effective, Safe in Black Men With Advanced Prostate Cancer
Study authors analyzed a total of 46 Black men with advanced prostate cancer enrolled in the phase 3 HERO study.
Niraparib With Abiraterone + Prednisone Improves Outcomes in HRR BM+ Metastatic Castration Resistant Prostate Cancer
The phase 3 MAGNITUDE study assessed niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC with or without alterations in homologous recombination repair associated genes.
Elevated PSA at Midlife Predicts Aggressive Prostate Cancer in Blacks
A midlife PSA value above the 90th percentile was associated with greater risk of total and aggressive prostate cancer in black men.
Annual PSA Screening Best for Reducing Prostate Cancer Deaths
A study of 400,887 men in an integrated health system, the first to evaluate various PSA screening intervals and age groups, concluded that yearly screening is the interval of choice.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...